SAN DIEGO —
Faro Health Inc., the leading AI-powered platform for data-driven clinical protocol design, today announced it has partnered with Recursion (NASDAQ: RXRX) to accelerate and optimize clinical protocol design for Recursion’s portfolio of clinical-stage drug candidates.
Recursion, the leading clinical-stage TechBio company decoding biology to industrialize drug discovery, has made significant strides in recent months in advancing its end-to-end platform, spanning discovery, biology, chemistry, and clinical development. In November 2024, Recursion officially merged with Exscientia, resulting in a post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs. As Recursion looks to advance these programs in 2025 and beyond, the company sought a technology partner aligned to Recursion’s mission of making drug discovery and development increasingly data-driven and efficient through AI/ML enabled platform technology.
To learn more: Press Release: Faro Health logo Faro Health and Recursion Partner To Advance AI-powered Clinical Trial Design
